Concepedia

Peter D. Senter

PD

Statistics

Publications

78

Citations

12.6K

H-Index

47

Active since

1977

Affiliations

Seagen (United States)(Current)

Bristol-Myers Squibb (United States)

Fred Hutch Cancer Center

University of Washington

Peter D. Senter is an author at Seagen (United States) specializing in pharmacy, pharmacology, and antibody-drug conjugates.

ORCID

Publications per year

1977–2020

78

Publications

78

Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate

Kevin J. Hamblett, Peter D. Senter, Dana F. Chace et al. · Clinical Cancer Research · 2004 · 1.2K citations

, , +17

Development of potent monoclonal antibody auristatin conjugates for cancer therapy

Svetlana O. Doronina, Brian E. Toki, Michael Torgov et al. · Nature Biotechnology · 2003 · 1.2K citations

, , +14

cAC10-vcMMAE, an anti-CD30–monomethyl auristatin E conjugate with potent and selective antitumor activity

Joseph A. Francisco, Charles G. Cerveny, Damon L. Meyer et al. · Blood · 2003 · 921 citations

, , +11

The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma

Peter D. Senter, Eric L. Sievers · Nature Biotechnology · 2012 · 752 citations

, , +15

Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index

Robert P. Lyon, Tim D. Bovee, Svetlana O. Doronina et al. · Nature Biotechnology · 2015 · 523 citations

, , +14

1–5 of 78